Radioembolization for Primary and Metastatic Tumors of the Liver
Summary
The policy considers yttrium-90 microsphere radioembolization medically necessary for primary hepatocellular carcinoma that is unresectable and limited to the liver, as a bridge to liver transplantation, and for primary intrahepatic cholangiocarcinoma in individuals with unresectable tumors. It also considers radioembolization medically necessary for hepatic metastases from neuroendocrine tumors with diffuse and symptomatic disease when systemic therapy has failed to control symptoms. It may be considered medically necessary for unresectable hepatic metastases from colorectal carcinoma, melanoma (ocular or cutaneous), or breast cancer that are both progressive and diffuse, in individuals with liver-dominant disease who are refractory to chemotherapy or are not candidates for chemotherapy or other systemic therapies. Radioembolization is investigational for all other hepatic metastases and for all other indications not described.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.